July 11, 2001

Daniel Tripodi, Ph.D.
The Sage Group, Inc.
245 Route 22 West, Suite 304
Bridgewater, NJ 08807

Re: Baxter International Inc.
Docket No. C-3726

Dear Dr. Tripodi:

This letter is to inform you that, pursuant to Paragraph V.C.8. of the above referenced order, the Commission has approved your March 26, 2001, request that the Commission extend the period for twelve (12) months, through July 28, 2002, during which Haemacure Corporation may continue to seek to obtain all necessary FDA approvals to manufacture Fibrin Sealant for sale in the United States.

By direction of the Commission.

Donald S. Clark
Secretary

cc: Michael Sennett, Esq.
Bell, Boyd & Lloyd
Three First National Plaza
70 West Madison Street, Suite 3300
Chicago, IL 60602-4207

James F. Stern, Esq.
Foley & Lardner
Firstar Center
777 West Wisconsin Avenue
Milwaukee, WI 53202-5367